IntegraGen Partners with Twist Bioscience

IntegraGen today announced the addition of Twist Bioscience Corporation’s Human Core Exome Complete Kit, a streamlined library prep and exome enrichment solution, to its next-generation targeted sequencing product offerings. Under the terms of the agreement Twist Bioscience will provide IntegraGen its Human Core Exome Complete Kit for all target (…)  » 

IntegraGen and GoPath Laboratories sign licensing agreement for miR-31-3p test in North America

IntegraGen and GoPath Laboratories announced today the signing of a non-exclusive licensing agreement allowing GoPath to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to physicians in the United States and Canada. The test will complement GoPath’s specialized molecular diagnostic testing portfolio for cancer and enable clinicians to (…)  » 

IntegraGen to attend the Jefferies 2017 London Healthcare Conference

IntegraGen will participate in The Jefferies 2017 London Healthcare Conference taking place 15 and 16 November 2017 in London, UK.

The Jefferies Conference is the largest healthcare-dedicated conference in Europe with over 350 participating companies, 1,400 attendees and 3,400 business-to-business and investor meetings. The event will feature (…)  » 

IntegraGen announces miR-31-3p publication in Oncotarget

IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…)  »